{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:53:58Z","timestamp":1778745238514,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T00:00:00Z","timestamp":1416873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s40265-014-0328-z","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T14:45:54Z","timestamp":1417531554000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Dextromethorphan\/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect"],"prefix":"10.1007","volume":"75","author":[{"given":"Lily P. H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,25]]},"reference":[{"issue":"1","key":"328_CR1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/jnp.2009.21.1.75","volume":"21","author":"J Parvizi","year":"2009","unstructured":"Parvizi J, Coburn KL, Shillcutt SD, et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2009;21(1):75\u201387.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"7","key":"328_CR2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/ern.11.68","volume":"11","author":"A Miller","year":"2011","unstructured":"Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011;11(7):1077\u201388.","journal-title":"Expert Rev Neurother."},{"issue":"11","key":"328_CR3","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4065\/81.11.1482","volume":"81","author":"J Parvizi","year":"2006","unstructured":"Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc. 2006;81(11):1482\u20136.","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"328_CR4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","volume":"207","author":"LL Werling","year":"2007","unstructured":"Werling LL, Keller A, Frank JG, et al. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248\u201357.","journal-title":"Exp Neurol."},{"key":"328_CR5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2165\/11591450-000000000-00000","volume":"71","author":"EP Pioro","year":"2011","unstructured":"Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs. 2011;71:1193\u2013207.","journal-title":"Drugs."},{"issue":"23","key":"328_CR6","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.lfs.2005.04.025","volume":"77","author":"JF Marier","year":"2005","unstructured":"Marier JF, Deschenes JL, Hage A, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 2005;77(23):2911\u201326.","journal-title":"Life Sci."},{"key":"328_CR7","unstructured":"European Medicines Agency. Nuedexta (dextromethorphan\/quinidine) oral capsules: EU summary of product characteristics. http:\/\/www.ema.europa.eu . Accessed 5 Nov 2014."},{"key":"328_CR8","unstructured":"Avanir Pharmaceuticals Inc. Nuedexta\u00ae (dextromethorphan hydrobromide and quinidine sulfate) oral capsules: US prescribing information. 2010. https:\/\/www.nuedexta.com . Accessed 5 Nov 2014."},{"issue":"3","key":"328_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1468-1331.2011.03501.x","volume":"19","author":"PM Andersen","year":"2012","unstructured":"Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360\u201375.","journal-title":"Eur J Neurol."},{"issue":"15","key":"328_CR10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227\u201333.","journal-title":"Neurology."},{"issue":"3","key":"328_CR11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","volume":"274","author":"EE Codd","year":"1995","unstructured":"Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263\u201370.","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"328_CR12","doi-asserted-by":"crossref","first-page":"e89985","DOI":"10.1371\/journal.pone.0089985","volume":"9","author":"L Nguyen","year":"2014","unstructured":"Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985.","journal-title":"PLoS One."},{"issue":"5","key":"328_CR13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JCP.0b013e3181b5ae5c","volume":"29","author":"G Haiman","year":"2009","unstructured":"Haiman G, Pratt H, Miller A. Effects of dextromethorphan\/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J Clin Psychopharmacol. 2009;29(5):444\u201352.","journal-title":"J Clin Psychopharmacol."},{"issue":"S16","key":"328_CR14","first-page":"S65","volume":"72","author":"BR Brooks","year":"2012","unstructured":"Brooks BR, Bravver E, Desai UG, et al. Bulbar speech-articulation\/swallowing rate changes measured in amyotrophic lateral sclerosis (ALS) patients treated with dextromethorphan\/quinidine(nuedexta) for pseudobulbar affect (PBA)-determination of treatment effect size for future clinical trials [abstract no. M1408]. Ann Neurol. 2012;72(S16):S65\u20136.","journal-title":"Ann Neurol."},{"issue":"1","key":"328_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hup.1086","volume":"25","author":"LA Zawertailo","year":"2010","unstructured":"Zawertailo LA, Tyndale RF, Busto U, et al. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol. 2010;25(1):71\u20139.","journal-title":"Hum Psychopharmacol."},{"key":"328_CR16","unstructured":"European Medicines Agency. Neudexta (dextromethorphan\/quinidine): assessment report for an initial marketing authorisation application. 25 Apr 2013. http:\/\/www.ema.europa.eu . Accessed 5 Nov 2014."},{"issue":"5","key":"328_CR17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693\u2013702.","journal-title":"Ann Neurol."},{"issue":"10","key":"328_CR18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0091270004269521","volume":"44","author":"LE Pope","year":"2004","unstructured":"Pope LE, Khalil MH, Berg JE, et al. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004;44(10):1132\u201342.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"328_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0009-9236(96)90056-9","volume":"60","author":"DA Capon","year":"1996","unstructured":"Capon DA, Bochner F, Kerry N, et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60(3):295\u2013307.","journal-title":"Clin Pharmacol Ther."},{"issue":"8","key":"328_CR20","first-page":"e1","volume":"32","author":"LE Pope","year":"2012","unstructured":"Pope LE, Schoedel KA, Bartlett C, et al. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan\/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012;32(8):e1\u201315.","journal-title":"Clin Drug Investig."},{"issue":"4","key":"328_CR21","first-page":"380","volume":"75","author":"E Pioro","year":"2010","unstructured":"Pioro E, Brooks B, Cummings J, et al. Persistent efficacy of dextromethorphan (DM)\/quinidine (Q) for pseudobulbar affect (PBA): results from a 12-week, open-label extension (OLE) study [abstract no. LBS.006]. Neurology. 2010;75(4):380.","journal-title":"Neurology."},{"key":"328_CR22","unstructured":"Doody RS, D\u2019Amico S, Cutler AJ, et al. Safety, tolerability, and effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in patients with Alzheimer\u2019s disease\/dementia: PRISM II [poster no. M1334WIP]. In: 139th Annual Meeting of the American Neurological Association, Baltimore (MD); 2014."},{"key":"328_CR23","unstructured":"Avanir Pharmaceuticals. Safety and efficacy of AVP-923 in PBA patients with ALS or MS (STAR) [ClinicalTrial.gov identifier NCT00573443]. US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/www.clinicaltrials.gov . Accessed 5 Nov 2014."},{"key":"328_CR24","unstructured":"Jillapalli D. US FDA center for drug evaluation and research: medical review of Zenvia. 25 Sep 2010. http:\/\/www.accessdata.fda.gov . Accessed 30 Aug 2013."},{"key":"328_CR25","unstructured":"Pioro E, Brooks B, Cummings J, et al. Safety and tolerability of dextromethorphan\/quinidine for pseudobulbar affect in a 12-week, open-label extension study [abstract no. P06.128]. In: 62nd Annual Meeting of the American Academy of Neurology, Toronto (ON); 2010."},{"key":"328_CR26","unstructured":"Siffert J, Abijo O, Formella A. Dextromethorphan 20\u00a0mg\/quinidine 10\u00a0mg effectiveness and tolerability in treating PBA in patients with stroke, dementia and other neurological conditions: results of a retrospective chart review [abstract]. Consult Pharm. 2013;28(10)."},{"issue":"6","key":"328_CR27","first-page":"325","volume":"38","author":"MP Cruz","year":"2013","unstructured":"Cruz MP. Nuedexta for the treatment of pseudobulbar affect. Drug Forcast. 2013;38(6):325\u20138.","journal-title":"Drug Forcast."},{"issue":"11","key":"328_CR28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1185\/03007995.2014.940040","volume":"30","author":"GL Pattee","year":"2014","unstructured":"Pattee GL, Wymer JP, Lomen-Hoerth C, et al. An open-label multicenter study to assess the safety of dextromethorphan\/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014;30(11):2255\u201365.","journal-title":"Curr Med Res Opin"},{"key":"328_CR29","unstructured":"Cummings JL. Neuropsychiatric inventory: comprehensive assessment of psychopathology in patients with dementia. 2009. http:\/\/www.dementia-assessment.com.au\/behavioural\/index.html . Accessed 5 Nov 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0328-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0328-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:26:44Z","timestamp":1747175204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0328-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0328-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,25]]}}}